C-squared Pharma

Activities: Ingredients

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    From proof-of-concept to commercial reality: a turning point for microneedle drug delivery A 50% reduction in microarray patch production costs demonstrates that scalable, automated MAP manufacturing is now commercially viable — clearing a critical barrier to...
  2. The future of aseptic manufacturing: Compact and advanced solutions As the pharmaceutical industry advances into more complex modalities, from biologics to cell and gene therapies, the need for flexible, aseptically robust fill-finish solutions...
  3. Destination Russia for new NYK Logistics warehouse Logistics specialist NYK is expanding its market presence with the launch of new warehousing operation in Moscow, Russia.
  4. Labtex Labtex is a specialist laboratory and process chemistry equipment solutions provider. A dynamic team of professionals with expertise in research and process development across...
  5. Lonza and Genetix extend commercial manufacturing agreement for ZYNTEGLO™ Expanded collaboration will support growing demand for FDA-approved gene therapy for beta-thalassemia

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

Related Content

Manufacturing

C2 PHARMA receives CEP approval for Oxybuprocaine hydrochloride

C2 PHARMA proudly announces the approval of a Certificate of Suitability (CEP) for Oxybuprocaine hydrochloride by the European Directorate for the Quality of Medicines and Health Care (EDQM)
Manufacturing

C2 PHARMA marks 10 years at CPHI Milan with expanded ophthalmic APIs

The complany is ready to showcase its expanding ophthalmic API portfolio and global regulatory filings, featuring Naphazoline Hydrochloride and Tropicamide
Ingredients

C2 PHARMA expands ophthalmic API portfolio with Naphazoline Hydrochloride launch

C2 PHARMA, the global leader in ophthalmic and niche active pharmaceutical ingredients (APIs), proudly announces the launch of its latest API, Naphazoline Hydrochloride
Regulatory

C2 Pharma's Tropicamide receives CEP from the European Directorate

The CEP approval of the ophthalmic drug allows C2 Pharma to distribute Tropicamide globally
Ingredients

C2 PHARMA announces upcoming launch of new oxybuprocaine hydrochloride API

C2 PHARMA excited to announce the upcoming launch of its new API, oxybuprocaine HCL, an ingredient that will be manufactured by manufacturing partner Laurus Labs
Ingredients

C2 Pharma to participate in DCAT Week 2024

The C2 PHARMA team will be located in the Benjamin hotel in Suite 2202
Ingredients

C2 PHARMA receives DMF approval in China for pilocarpine nitrate

C2 PHARMA announces the approval of a C-DMF for pilocarpine nitrate — granted on 30 October 2023 — an API manufactured by our Brazilian partner Anidro do Brasil
Subscribe now